昭衍新藥(06127.HK)預計前三季度淨利潤大幅增加約144.8%-164.8%
格隆匯10月18日丨昭衍新藥(06127.HK)公吿,2022年1-9月份公司實現歸屬於上市公司股東的淨利潤人民幣60,723.25萬元至人民幣65,683.38萬元與上年同期的財務報表數據相比,將增加約人民幣35,922.64萬元到人民幣40,882.76萬元,同比增加約144.8%到164.8%。
實現歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期的財務報表數據相比,將增加約人民幣36,640.33萬元到人民幣40,986.83萬元,同比增加約168.6%到188.6%。剔除未實現的生物資產公允價值變動收益、利息收入及匯兑損益的影響後,歸屬於上市公司股東的扣除非經常性損益的淨利潤與上年同期的財務報表數據相比,同比增加約61.0%到81.0%。
公司業績保持較好增長,主要歸因於以下因素:(i)公司始終強化技術創新,持續加強對創新型藥物的研發支持,深得創新型研發企業信賴;(ii)為保證在手訂單的順利交付,公司進一步增加產能,同時合理規劃項目排期,進一步提升了產能利用率;持續增加科研技術團隊規模,擁有越來越多的成熟技術人員,為業務增長提供了有力保障;(iii)公司進一步統籌資源,持續推進和加強上游產業鏈供應環節的工作,保障和提升了公司的持續服務能力;(iv)公司的資金管理為業績帶來了積極影響。
非經常性損益的影響:主要受政府補助、交易性金融資產收益、收購負商譽等多因素影響,扣除所得税後非經常性損益對淨利潤的影響金額約人民幣2,660萬元,與去年同期基本持平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.